- Home
- LGI vs KROS Comparison
LGI vs KROS Comparison
Compare LGI & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LGI | KROS |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.7M | 222.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LGI | KROS |
|---|---|---|
| Price | $16.46 | $9.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.83 |
| AVG Volume (30 Days) | 48.7K | ★ 146.3K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.32 | $9.69 |
| 52 Week High | $19.88 | $22.55 |
Technical Indicators
Market Signals| Indicator | LGI | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 44.80 | 33.76 |
| Support Level | $16.20 | N/A |
| Resistance Level | $16.85 | $11.86 |
| Average True Range (ATR) | 0.27 | 0.58 |
| MACD | 0.03 | -0.18 |
| Stochastic Oscillator | 42.22 | 15.14 |
Price Performance
Historical ComparisonAbout LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.